1. Stocks
  2. Neurocrine Biosciences, Inc.
  3. Swot
swot-logo

Neurocrine Biosciences, Inc. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

Neurocrine Biosciences, Inc. has 14 Strengths, 12 Weaknesses, 4 Opportunities and 1 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential

Add SWOT widget to your site/app

Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE

Buy Zone: Stocks in the buy zone based on days traded at current PE and P/BV

Relative Outperformance versus Industry over 1 Week

Mid-range Performer (DVM)

Annual Profit Growth higher than Sector Profit Growth

PEG lower than Industry PEG

Increasing Revenue every Quarter for the past 8 Quarters

Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year

Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Company with Low Debt

Increasing Revenue every Quarter for the past 4 Quarters

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Stocks with Quarter Change % less than Industry

PE higher than Industry PE

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Top Losers

Near 52 Week Low

Declining Net Cash Flow : Companies not able to generate net cash

Weak Momentum: Price below Short, Medium and Long Term Averages

Recent Results: Declining Operating Profit Margin and Net Profits (YoY)

RSI indicating price weakness

Near 52 Week Low

Top Losers

Stocks Underperforming their Industry Price Change in the Quarter

Mutual Funds Increased Shareholding in Past Month

Mutual Funds Increased Shareholding over the Past Two Months

MFs increased their shareholding last quarter

Mf buying for 2 months

Institutions decreased their shareholding last quarter

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks